Indian Vaccinations per Capita Raises Questions About BJP Rhetoric on Giftaid to Neighbours

[Bambi]

Except that...

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Taking safety, immunogenicity, and production capacity into account, the 3 μg dose of CoronaVac is the suggested dose for efficacy assessment in future phase 3 trials.

www.thelancet.com

Sinovac is validated with published phase 1 and phase 2 data and ongoing phase 3 data collection. That is the standard required for vaccine validation everywhere as per WHO guidance.

How's the Bharat vaccine going? Last I heard, Somani sahib assured Indians that it was validated "in clinical trial mode". Is it still in clinical trial mode (I.e. India has no published data to support its authorisation of this vaccine, so it is continuing its "trial" phase 1/2 data collection after the official rollout)?

Here's what Bharat vaccine has published in the Lancet. Note that it is barely out of phase 1, and actual data in the publication is limited. This is in sharp contrast to what Sinopharm published in the same journal, and in contrast to what other vaccine studies have published in USA, UK etc.

“BBV152 (Covaxin) led to tolerable safety outcomes and enhanced immune responses. Both Algel-IMDG formulations were selected for phase 2 immunogenicity trials. Further efficacy trials are warranted," the results said.

As I predicted, all hell has indeed broken loose over India's shoddy workmanship and corner-cutting...this is the BMJ, not some two bit tabloid:


"NewsIndia: Doctors call for investigation into allegations of ethical abuse in covid-19 vaccine trial
BMJ 2021; 372 doi: https://doi.org/10.1136/bmj.n131 (Published 14 January 2021)Cite this as: BMJ 2021;372:n131
Read our latest coverage of the coronavirus outbreak

• Article
• Metrics
• Responses

1. India Correspondent BMJ
2. Author affiliations

Multiple health groups in India have called for an investigation into allegations of ethical violations during a clinical trial of a covid-19 vaccine developed jointly by India’s Bharat Biotech and the Indian Council of Medical Research.
In a statement released on 14 January, groups of doctors and health rights advocates asked the Indian government to halt the trial at the People’s Hospital in Bhopal, exclude any data from the site during trial analysis, and take action against those responsible for violations.
The Bharat Biotech vaccine is among two covid-19 vaccines granted accelerated approval on 3 January by India’s drug regulatory authority for restricted emergency use, relying on safety and immunogenicity data without efficacy data.1
India has also approved the Oxford AstraZeneca vaccine, after reviewing safety, immunogenicity, and efficacy data from outside India and safety and immunogenicity data in India. A trial to evaluate the efficacy of the Bharat Biotech vaccine has enrolled 25 800 participants at 25 sites in 12 cities.
Seven participants enrolled in the trial by the People’s Hospital have claimed that they were not informed that they would receive either a vaccine or a placebo. In testimonies at a press conference on 10 January, the participants said that they were told that they would receive a vaccine that would protect them from the novel coronavirus and had been paid Rs750 (£7.5; €8.6; $10.3) to have the injections"

India: Doctors call for investigation into allegations of ethical abuse in covid-19 vaccine trial

Multiple health groups in India have called for an investigation into allegations of ethical violations during a clinical trial of a covid-19 vaccine developed jointly by India’s Bharat Biotech and the Indian Council of Medical Research. In a statement released on 14 January, groups of doctors...

www.bmj.com

Read it all so the question remains. When will you start vaccination with the china vaccines
Give me a date

 

[Chhatrapati]

Second biggest investor? Quote your sources please. This is from the UK Government portal citing their 2018 figures.

The ONS has India at 18th position,not 2nd, so I'm not sure what nonsensical Indian tabloid is providing you with scholarly articles, but I suggest you do a fact check.

UK foreign direct investment, trends and analysis - Office for National Statistics

Analysis of the impact of foreign direct investment (FDI) implied rates of return on the UK current account with insights from industry-level analysis.

www.ons.gov.uk

I noticed a couple of Indian newspapers mention this "second biggest investor" nonsense - which upon further inspection appears to relate to numbers of investments, not the actual value of wealth invested.

I could invest a few thousand quid in 100 cornershops and Patel jewellers today but that isn't going to help UK's economy.

I like how your entire talking point became investments in the UK.

Where you started.

Indian is giving away vaccine at the expense of it's public.

SII is a sweatshop.

There is a fire in SII.

Ended with, yo India is not largest in the UK it's only largest in terms of number of projects. lol

 

[masterchief_mirza]

@Bambi
Findings
Between April 16 and April 25, 2020, 144 participants were enrolled in the phase 1 trial, and between May 3 and May 5, 2020, 600 participants were enrolled in the phase 2 trial. 743 participants received at least one dose of investigational product (n=143 for phase 1 and n=600 for phase 2; safety population). In the phase 1 trial, the incidence of adverse reactions for the days 0 and 14 cohort was seven (29%) of 24 participants in the 3 ug group, nine (38%) of 24 in the 6 μg group, and two (8%) of 24 in the placebo group, and for the days 0 and 28 cohort was three (13%) of 24 in the 3 μg group, four (17%) of 24 in the 6 μg group, and three (13%) of 23 in the placebo group. The seroconversion of neutralising antibodies on day 14 after the days 0 and 14 vaccination schedule was seen in 11 (46%) of 24 participants in the 3 μg group, 12 (50%) of 24 in the 6 μg group, and none (0%) of 24 in the placebo group; whereas at day 28 after the days 0 and 28 vaccination schedule, seroconversion was seen in 20 (83%) of 24 in the 3 μg group, 19 (79%) of 24 in the 6 μg group, and one (4%) of 24 in the placebo group. In the phase 2 trial, the incidence of adverse reactions for the days 0 and 14 cohort was 40 (33%) of 120 participants in the 3 μg group, 42 (35%) of 120 in the 6 μg group, and 13 (22%) of 60 in the placebo group, and for the days 0 and 28 cohort was 23 (19%) of 120 in the 3 μg group, 23 (19%) of 120 in the 6 μg group, and 11 (18%) of 60 for the placebo group. Seroconversion of neutralising antibodies was seen for 109 (92%) of 118 participants in the 3 μg group, 117 (98%) of 119 in the 6 μg group, and two (3%) of 60 in the placebo group at day 14 after the days 0 and 14 schedule; whereas at day 28 after the days 0 and 28 schedule, seroconversion was seen in 114 (97%) of 117 in the 3 μg group, 118 (100%) of 118 in the 6 μg group, and none (0%) of 59 in the placebo group."

The requisite data for Sinopharm is published, hence the vaccine was approved.

Please post a comparable summary of Bharat vaccine documenting phase 1 and phase 2 outcomes, seroconversion, adverse events, then come and spout on this thread.

The problem you have @Bambi unlike the other Indian posters, is that you in particular forget that we have had an identical conversation hardly a day ago where I posted similar arguments and handed your *** back to you on a plate. Don't bang on about your pseudo scientific theories unless you can back it up.

 

[Bambi]

@Bambi
Findings
Between April 16 and April 25, 2020, 144 participants were enrolled in the phase 1 trial, and between May 3 and May 5, 2020, 600 participants were enrolled in the phase 2 trial. 743 participants received at least one dose of investigational product (n=143 for phase 1 and n=600 for phase 2; safety population). In the phase 1 trial, the incidence of adverse reactions for the days 0 and 14 cohort was seven (29%) of 24 participants in the 3 ug group, nine (38%) of 24 in the 6 μg group, and two (8%) of 24 in the placebo group, and for the days 0 and 28 cohort was three (13%) of 24 in the 3 μg group, four (17%) of 24 in the 6 μg group, and three (13%) of 23 in the placebo group. The seroconversion of neutralising antibodies on day 14 after the days 0 and 14 vaccination schedule was seen in 11 (46%) of 24 participants in the 3 μg group, 12 (50%) of 24 in the 6 μg group, and none (0%) of 24 in the placebo group; whereas at day 28 after the days 0 and 28 vaccination schedule, seroconversion was seen in 20 (83%) of 24 in the 3 μg group, 19 (79%) of 24 in the 6 μg group, and one (4%) of 24 in the placebo group. In the phase 2 trial, the incidence of adverse reactions for the days 0 and 14 cohort was 40 (33%) of 120 participants in the 3 μg group, 42 (35%) of 120 in the 6 μg group, and 13 (22%) of 60 in the placebo group, and for the days 0 and 28 cohort was 23 (19%) of 120 in the 3 μg group, 23 (19%) of 120 in the 6 μg group, and 11 (18%) of 60 for the placebo group. Seroconversion of neutralising antibodies was seen for 109 (92%) of 118 participants in the 3 μg group, 117 (98%) of 119 in the 6 μg group, and two (3%) of 60 in the placebo group at day 14 after the days 0 and 14 schedule; whereas at day 28 after the days 0 and 28 schedule, seroconversion was seen in 114 (97%) of 117 in the 3 μg group, 118 (100%) of 118 in the 6 μg group, and none (0%) of 59 in the placebo group."

The requisite data for Sinopharm is published, hence the vaccine was approved.

Please post a comparable summary of Bharat vaccine documenting phase 1 and phase 2 outcomes, seroconversion, adverse events, then come and spout on this thread.

The problem you have @Bambi unlike the other Indian posters, is that you in particular forget that we have had an identical conversation hardly a day ago where I posted similar arguments and handed your *** back to you on a plate. Don't bang on about your pseudo scientific theories unless you can back it up.

Where did I have a conversation with you about vaccines?
this is the 2 Nd time I am talking to you the first one was on the Chinese soilder thread

 

[achhu]

View attachment 709823

Most of the countries on this list have no domestic vaccine production facilities (whether for a rebranded foreign product or a homegrown vaccine). USA, UK, Russia and China have all produced a vaccine but have simultaneously managed to coordinate a satisfactory domestic rollout as well as make good on international deliveries (either for profit, cost-price or as gifted doses to allies).

The one other vaccine producer which is notable for its absence from this list is India. For reference, the same source website puts India at 0.1 per 100 people as of 22nd Jan.

As multiple pdf-ers have alluded to, profiteering during a pandemic may well be an important consideration for some nations. Ethical considerations of pandemic profiteering aside, is there any justification for beating one's chest over income projections for exported vaccines while one's own population is lagging behind severely in terms of vaccinations per capita?
In November, India had secured a vast stock of vaccines.

"India, for example, has secured more than 2 billion doses of vaccine, in part by leveraging access to the manufacturing capabilities of the Serum Institute of India in Pune, the world’s largest vaccine maker."

Did India put profiteering and exporting and "vaccine diplomacy" ahead of a coordinated drive to protect its own people?

How COVID vaccines are being divvied up around the world

Canada leads the pack in terms of doses secured per capita.

www.nature.com

A 2 billion dose headstart seems to have evaporated in favour of the usual BJP chestbeating about gifts to Bhutan and the Maldives.

enemies are again in pain .

 

[masterchief_mirza]

Where did I have a conversation with you about vaccines?
this is the 2 Nd time I am talking to you the first one was on the Chinese soilder thread

Do you know what, I may be wrong....I apologise if that's the case....all Indians are just blurring into one around here these days.

 

[Chhatrapati]

How's the Bharat vaccine going? Last I heard, Somani sahib assured Indians that it was validated "in clinical trial mode". Is it still in clinical trial mode (I.e. India has no published data to support its authorisation of this vaccine, so it is continuing its "trial" phase 1/2 data collection after the official rollout)?

It is doing fine, it is given to hundreds of thousands of candidates "in clinical trial mode" and under emergency use protocols.

 

[achhu]

On the contrary my dear fellow! I claimed India has not vaccinated enough people, nor am I confident it will achieve the rate of vaccinations seen elsewhere. I even stated that India has a huge stockpile of vaccines. Anyway, we could bicker all day. Let's wait and see.

when you will start producing vaccine to give friendly nations like malaysia and turkey ?

 

[Bambi]

Do you know what, I may be wrong....I apologise if that's the case....all Indians are just blurring into one around here these days.

When will you start vaccination with the china vaccines?
Give me a date

 

[achhu]

When will you start vaccination with the china vaccines?
Give me a date

depends on china .

 

[Bambi]

depends on china .

Don't talk to me buddy

 

[masterchief_mirza]

It is doing fine, it is given to hundreds of thousands of candidates "in clinical trial mode" and under emergency use protocols.

My dear associate from the eastern hinterlands, there is no such recognised legal concept in vaccine or drug administration as offering a therapeutic intervention "in clinical trial mode". One is either conducting a controlled trial with all the usual ethical and operational checkpoints in place, or one is offering a validated intervention. Otherwise we reduce ourselves to quackery.

I'm sure someone among India's highly educated medical establishment will ask Somani for further clarification on his usage of this highly suspect phraseology.

 

[IsThisNameAvailable]

I can say with certainty Pakistan will never ever be able to achieve this

Kindly refrain from comparing India with Pakistan.

+1
Kindly refrain

 

[khanmubashir]

View attachment 709823

Most of the countries on this list have no domestic vaccine production facilities (whether for a rebranded foreign product or a homegrown vaccine). USA, UK, Russia and China have all produced a vaccine but have simultaneously managed to coordinate a satisfactory domestic rollout as well as make good on international deliveries (either for profit, cost-price or as gifted doses to allies).

The one other vaccine producer which is notable for its absence from this list is India. For reference, the same source website puts India at 0.1 per 100 people as of 22nd Jan.

As multiple pdf-ers have alluded to, profiteering during a pandemic may well be an important consideration for some nations. Ethical considerations of pandemic profiteering aside, is there any justification for beating one's chest over income projections for exported vaccines while one's own population is lagging behind severely in terms of vaccinations per capita?
In November, India had secured a vast stock of vaccines.

"India, for example, has secured more than 2 billion doses of vaccine, in part by leveraging access to the manufacturing capabilities of the Serum Institute of India in Pune, the world’s largest vaccine maker."

Did India put profiteering and exporting and "vaccine diplomacy" ahead of a coordinated drive to protect its own people?

How COVID vaccines are being divvied up around the world

Canada leads the pack in terms of doses secured per capita.

www.nature.com

A 2 billion dose headstart seems to have evaporated in favour of the usual BJP chestbeating about gifts to Bhutan and the Maldives.

The Oxford vaccine is licensed to India but is also committed to other nations so had to be exported as it's British IP

View attachment 709823

Most of the countries on this list have no domestic vaccine production facilities (whether for a rebranded foreign product or a homegrown vaccine). USA, UK, Russia and China have all produced a vaccine but have simultaneously managed to coordinate a satisfactory domestic rollout as well as make good on international deliveries (either for profit, cost-price or as gifted doses to allies).

The one other vaccine producer which is notable for its absence from this list is India. For reference, the same source website puts India at 0.1 per 100 people as of 22nd Jan.

As multiple pdf-ers have alluded to, profiteering during a pandemic may well be an important consideration for some nations. Ethical considerations of pandemic profiteering aside, is there any justification for beating one's chest over income projections for exported vaccines while one's own population is lagging behind severely in terms of vaccinations per capita?
In November, India had secured a vast stock of vaccines.

"India, for example, has secured more than 2 billion doses of vaccine, in part by leveraging access to the manufacturing capabilities of the Serum Institute of India in Pune, the world’s largest vaccine maker."

Did India put profiteering and exporting and "vaccine diplomacy" ahead of a coordinated drive to protect its own people?

How COVID vaccines are being divvied up around the world

Canada leads the pack in terms of doses secured per capita.

www.nature.com

A 2 billion dose headstart seems to have evaporated in favour of the usual BJP chestbeating about gifts to Bhutan and the Maldives.

The Oxford vaccine is licensed to India but is also committed to other nations so had to be exported as it's British IP

 

[IsThisNameAvailable]

It doesn't matter Mark my words Pakistan is begging for vaccines from China
Pakistan will never be able to vaccinate their population like India ever

Stop your ridiculous comparison please.

The pure land and its inhabitants need no vaccine.
Polio vaccine was refused by their movie star Fawad Khan recently. What % of average population is polio vaccinated, is anyone guess.

Your comparison is actually a display of inferiority complex. Please refrain.